Cart
sales@molnova.com
Home - Products - Angiogenesis - FGFR - Pemigatinib (INCB054828)

Pemigatinib (INCB054828)

CAS No. 1513857-77-6

Pemigatinib (INCB054828)( INCB054828 )

Catalog No. M21751 CAS No. 1513857-77-6

Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 87 In Stock
10MG 140 In Stock
25MG 259 In Stock
50MG 405 In Stock
100MG 538 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Pemigatinib (INCB054828)
  • Note
    Research use only, not for human use.
  • Brief Description
    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.
  • Description
    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    INCB054828
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1513857-77-6
  • Formula Weight
    487.5
  • Molecular Formula
    C??H??F?N?O?
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and heat to 60°C)
  • SMILES
    CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. 2. Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. 3. Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Vofatamab

    Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.

  • FGF-401

    FGF-401 (NVP-FGF401, Roblitinib, FGF401)?is a first-in-class, potent, highly selective FGFR4 inhibitor with IC50 of 1.1 nM.

  • Infigratinib

    Infigratinib (NVP-BGJ398, BGJ398) is a potent, selective pan-FGFR inhibitor.

Sign In Join Free